{
    "id": "dbpedia_4976_0",
    "rank": 29,
    "data": {
        "url": "https://standuptocancer.org/research-finder-json-publications/",
        "read_more_link": "",
        "language": "en",
        "title": "Research Finder JSON Publications",
        "top_image": "https://standuptocancer.org/wp-content/uploads/2018/03/full_logo_001r-1.jpg",
        "meta_img": "https://standuptocancer.org/wp-content/uploads/2018/03/full_logo_001r-1.jpg",
        "images": [
            "https://www.facebook.com/tr?id=314212235841875&ev=PageView  &noscript=1",
            "https://standuptocancer.org/wp-content/themes/standuptocancer/img/header/su2c-logo.png",
            "https://standuptocancer.org/wp-content/themes/standuptocancer/img/footer/impossible_possible_logo_white.svg",
            "https://standuptocancer.org/wp-content/themes/standuptocancer/img/footer/impossible_possible_logo_white.svg",
            "https://standuptocancer.org/wp-content/uploads/2023/05/footer-logos-BBB.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2019-12-12T22:50:40+00:00",
        "summary": "",
        "meta_description": "{“posts”:[{“title”:”Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, […]",
        "meta_lang": "en",
        "meta_favicon": "https://standuptocancer.org/wp-content/themes/standuptocancer/favicon.png",
        "meta_site_name": "Stand Up To Cancer",
        "canonical_link": "https://standuptocancer.org/research-finder-json-publications/",
        "text": "{“posts”:[{“title”:”Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. Ann Oncol. 2020 Mar;31(3):404-411.”,”type”:”publication”,”url”:”https://www.annalsofoncology.org/article/S0923-7534(19)41721-3/fulltext”,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Annals of Oncology, 2020″,”pub_med_id”:”32067682″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32067682/”},{“title”:”Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.19.02105″,”cancer_type_terms_string”:”Other”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2020″,”pub_med_id”:”31682550″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31682550/”},{“title”:”Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 Jan 1;38(1):11-19.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.19.02107″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2020″,”pub_med_id”:”31725351″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31725351/”},{“title”:”Abe T, Koi C, Kohi S, Song KB, Tamura K, Macgregor-Das A, Kitaoka N, Chuidian M, Ford M, Dbouk M, Borges M, He J, Burkhart R, Wolfgang CL, Klein AP, Eshleman JR, Hruban RH, Canto MI, Goggins M. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020 May;18(5):1161-1169.e5. d”,”type”:”publication”,”url”:”https://www.cghjournal.org/article/S1542-3565(19)31238-8/fulltext”,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team: Intercepting Pancreatic Cancer in High-Risk Cohorts”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/pancreatic-interception-high-risk-cohorts-dream-team/”,”publisher_year”:”Clinical Gastroenterology and Hepatology, 2020″,”pub_med_id”:”31676359″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31676359/”},{“title”:”Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol. 2020 Feb;15(1):11-24.”,”type”:”publication”,”url”:”https://link.springer.com/article/10.1007%2Fs11523-019-00690-0″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Targeted Oncology, 2020″,”pub_med_id”:”31786718″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31786718/”},{“title”:”Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, Hong CB, Corcoran RB. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition. Clin Cancer Res. 2020 Apr 1;26(7):1633-1643.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/26/7/1633″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2020″,”pub_med_id”:”31776128″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31776128/”},{“title”:”Katagiri R, Song M, Zhang X, Lee DH, Tabung FK, Fuchs CS, Meyerhardt JA, Nishihara R, Chan AT, Joshi AD, Iwasaki M, Ogino S, Willett WC, Giovannucci E, Wu K. Dietary Intake of Branched-Chain Amino Acids and Risk of Colorectal Cancer. Cancer Prev Res (Phila). 2020 Jan;13(1):65-72.”,”type”:”publication”,”url”:”https://cancerpreventionresearch.aacrjournals.org/content/13/1/65″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Prevention”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Cancer Prevention Research, 2020″,”pub_med_id”:”31699705″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31699705/”},{“title”:”Zheng X, Wu K, Song M, Ogino S, Fuchs CS, Chan AT, Giovannucci EL, Cao Y, Zhang X. Yogurt consumption and risk of conventional and serrated precursors of colorectal cancer. Gut. 2020 May;69(5):970-972.”,”type”:”publication”,”url”:”https://gut.bmj.com/content/69/5/970.1″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Prevention”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Gut, 2020″,”pub_med_id”:”31209182″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31209182/”},{“title”:”Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 Apr 27.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-020-0827-2″,”cancer_type_terms_string”:”Brain/Nervous System, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Nature Medicine, 2020″,”pub_med_id”:”32341580″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32341580/”},{“title”:”Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, Schalper KA, Rimm DL. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clin Cancer Res. 2020 Feb 15;26(4):970-977.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/26/4/970″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2020″,”pub_med_id”:”31615933″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31615933/”},{“title”:”LoRusso PM, Schalper K, Sosman J. Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell Melanoma Res. 2020 May;33(3):390-402.”,”type”:”publication”,”url”:”https://onlinelibrary.wiley.com/doi/full/10.1111/pcmr.12847″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:”Immunotherapy, Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Pigment Cell & Melanoma Research, 2020″,”pub_med_id”:”31705737″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31705737/”},{“title”:”Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, Broeckaert MAM, Anagnostou V, Adleff V, Bruhm DC, Canzoniero JV, Fiksel J, Nordsmark M, Warmerdam FARM, Verheul HMW, van Spronsen DJ, Beerepoot LV, Geenen MM, Portielje JEA, Jansen EPM, van Sandick J, Meershoek-Klein Kranenbarg E, van Laarhoven HWM, van der Peet DL, van de Velde CJH, Verheij M, Fijneman R, Scharpf RB, Meijer GA, Cats A, Velculescu VE. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020 Jan 27;11(1):525.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41467-020-14310-3″,”cancer_type_terms_string”:”Stomach”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Nature Communications, 2020″,”pub_med_id”:”31988276″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31988276/”},{“title”:”Komor MA, Bosch LJ, Coupé VM, Rausch C, Pham TV, Piersma SR, Mongera S, Mulder CJ, Dekker E, Kuipers EJ, van de Wiel MA, Carvalho B, Fijneman RJ, Jimenez CR, Meijer GA, de Wit M. Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression. J Pathol. 2020 Mar;250(3):288-298.”,”type”:”publication”,”url”:”https://onlinelibrary.wiley.com/doi/full/10.1002/path.5369″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Journal of Pathology, 2020″,”pub_med_id”:”31784980″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31784980/”},{“title”:”Shi Y, Liu L, Hamada T, Nowak JA, Giannakis M, Ma Y, Song M, Nevo D, Kosumi K, Gu M, Kim SA, Morikawa T, Wu K, Sui J, Papantoniou K, Wang M, Chan AT, Fuchs CS, Meyerhardt JA, Giovannucci E, Ogino S, Schernhammer ES, Nishihara R, Zhang X. Night-Shift Work Duration and Risk of Colorectal Cancer According to IRS1 and IRS2 Expression. Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):133-140.”,”type”:”publication”,”url”:”https://cebp.aacrjournals.org/content/29/1/133″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Cancer Epidemiology, Biomarkers & Prevention, 2020″,”pub_med_id”:”31666286″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31666286/”},{“title”:”Goldberg JL, Navid F, Hank JA, Erbe AK, Santana V, Gan J, de Bie F, Javaid AM, Hoefges A, Merdler M, Carmichael L, Kim K, Bishop MW, Meager MM, Gillies SD, Pandey JP, Sondel PM. Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma. J Immunother Cancer. 2020 Mar;8(1).”,”type”:”publication”,”url”:”https://jitc.bmj.com/content/8/1/e000590″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Journal for Immunotherapy of Cancer, 2020″,”pub_med_id”:”32169872″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32169872/”},{“title”:”Yang RK, Kuznetsov IB, Ranheim EA, Wei JS, Sindiri S, Gryder BE, Gangalapudi V, Song YK, Patel V, Hank JA, Zuleger CL, Erbe AK, Morris ZS, Quale R, Kim K, Albertini MR, Khan J, Sondel PM. Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2. Clin Cancer Res. 2020 Mar 9. pii: clincanres.3294.2019.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/26/13/3296″,”cancer_type_terms_string”:”Melanoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2020″,”pub_med_id”:”32152202″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32152202/”},{“title”:”Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020 Feb 17;10(2):19.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41408-020-0284-7″,”cancer_type_terms_string”:”Multiple Myeloma”,”treatment_type_terms_string”:”Prevention”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Multiple Myeloma Dream Team: Screening and Interception of Precursor Myeloma”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/precursor-myeloma-dream-team/”,”publisher_year”:”Blood Cancer Journal, 2020″,”pub_med_id”:”32066732″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32066732/”},{“title”:”Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W, Noel P, Wartenberg M, Zlobec I, Eichmann M, Galván JA, Karamitopoulou E, Gilderman T, Esparza LA, Shima Y, Spahn P, French R, Lewis NE, Fisch KM, Sasik R, Rosenthal SB, Kritzik M, Von Hoff D, Han H, Ideker T, Deshpande AJ, Lowy AM, Adams PD, Reya T. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Cell. 2019 Apr 18;177(3):572-586.e22.”,”type”:”publication”,”url”:”https://www.cell.com/cell/fulltext/S0092-8674(19)30272-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867419302727%3Fshowall%3Dtrue”,”cancer_type_terms_string”:””,”treatment_type_terms_string”:””,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”publisher_year”:”Cell, 2020″,”pub_med_id”:”30955884″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/30955884/”},{“title”:”Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020 Feb;17(2):75-90.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41571-019-0266-5″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Epigenetic Therapy, Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”Van Andel Institute–SU2C Cancer Epigenetics Dream Team: The Epigenetics Dream Team II”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/epigenetics-dream-team-ii/”,”publisher_year”:”Nature Reviews Clinical Oncology, 2020″,”pub_med_id”:”31548600″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31548600/”},{“title”:”Giri J, Das R, Nylen E, Chinnadurai R, Galipeau J. CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury. Cell Rep. 2020 Feb 11;30(6):1923-1934.e4.”,”type”:”publication”,”url”:”https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30071-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124720300711%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Cell Reports, 2020″,”pub_med_id”:”32049021″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32049021/”},{“title”:”Hofmann I, Avagyan S, Stetson A, Guo D, Al-Sayegh H, London WB, Lehmann L. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. Biol Blood Marrow Transplant. 2020 Feb 20. pii: S1083-8791(20)30100-2.”,”type”:”publication”,”url”:”https://www.bbmt.org/article/S1083-8791(20)30100-2/fulltext”,”cancer_type_terms_string”:”Pediatric – Blood Related”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Biology of Blood and Marrow Transplantation, 2020″,”pub_med_id”:”32088370″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/32088370/”},{“title”:”Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 Jul 1;79(13):3251-3267.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/13/3251″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”31040157″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31040157″},{“title”:”Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M, Khorana AA. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2019 Jan 10;37(2):153-164.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.18.01489″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team: Intercepting Pancreatic Cancer in High-Risk Cohorts”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/pancreatic-interception-high-risk-cohorts-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2019″,”pub_med_id”:”30457921″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30457921″},{“title”:”Deng Y , Bao F, Dai Q, Wu LF, Altschuler SJ. Scalable analysis of cell-type composition from single-cell transcriptomics using deep recurrent learning. Nat Methods. 2019 Apr;16(4):311-314.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41592-019-0353-7″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Lung Cancer Convergence Research Team: Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-evolution-convergence-team/”,”publisher_year”:”Nature Methods, 2019″,”pub_med_id”:”30886411″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30886411″},{“title”:”Rajakulendran N, Rowland KJ, Selvadurai HJ, Ahmadi M, Park NI, Naumenko S, Dolma S, Ward RJ, So M, Lee L, MacLeod G, Pasiliao C, Brandon C, Clarke ID, Cusimano MD, Bernstein M, Batada N, Angers S, Dirks PB. Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells. Genes Dev. 2019 May 1;33(9-10):498-510.”,”type”:”publication”,”url”:”http://genesdev.cshlp.org/content/33/9-10/498″,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Genes & Development, 2019″,”pub_med_id”:”30842215″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30842215″},{“title”:”Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med. 2019 Feb;25(2):284-291.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-018-0274-5″,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”30559419″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30559419″},{“title”:”Choi H, Deng J, Li S, Silk T, Dong L, Brea EJ, Houghton S, Redmond D, Zhong H, Boiarsky J, Akbay EA, Smith PD, Merghoub T, Wong KK, Wolchok JD. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Rep. 2019 Apr 16;27(3):806-819.e5.”,”type”:”publication”,”url”:”https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30396-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124719303961%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Cell Reports, 2019″,”pub_med_id”:”30995478″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30995478″},{“title”:”Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019 May 28;12(583).”,”type”:”publication”,”url”:”https://stke.sciencemag.org/content/12/583/eaaw9450″,”cancer_type_terms_string”:”Lung, Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:””,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Science Signaling, 2019″,”pub_med_id”:”31138768″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31138768″},{“title”:”Toska E, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku M, Xu G, Park J, Minuesa G, Shifman SG, Socci ND, Koche R, Leslie CS, Scaltriti M, Baselga J. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Rep. 2019 Apr 2;27(1):294-306.e5.”,”type”:”publication”,”url”:”https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30297-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124719302979%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”publisher_year”:”Cell Reports, 2019″,”pub_med_id”:”30943409″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30943409″},{“title”:”Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019 Aug 1;25(15):4663-4673.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/15/4663″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”31053602″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31053602″},{“title”:”Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/6/1214″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”30541742″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30541742″},{“title”:”Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, Murison A, Kushida MM, Coutinho FJ, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Dirks PB, Pugh TJ, Morrissy S, St Croix B, Mahoney DJ, Lupien M, Gallo M. High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res. 2019 Aug;29(8):1211-1222.”,”type”:”publication”,”url”:”https://genome.cshlp.org/content/29/8/1211″,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Genome Research, 2019″,”pub_med_id”:”31249064″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31249064″},{“title”:”Abe T, Blackford AL, Tamura K, Ford M, McCormick P, Chuidian M, Almario JA, Borges M, Lennon AM, Shin EJ, Klein AP, Hruban RH, Canto MI, Goggins M. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. J Clin Oncol. 2019 May 1;37(13):1070-1080.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.18.01512″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team: Intercepting Pancreatic Cancer in High-Risk Cohorts”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/pancreatic-interception-high-risk-cohorts-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2019″,”pub_med_id”:”30883245″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30883245″},{“title”:”Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 Jun;570(7761):385-389.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41586-019-1272-6″,”cancer_type_terms_string”:”Bile Duct, Breast, Colorectal, Lung, Ovarian, Pancreatic, Stomach”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Nature, 2019″,”pub_med_id”:”31142840″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31142840″},{“title”:”Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, White JR, Lu S, Verner EL, Ruan F, Riley D, Anders RA, Gedvilaite E, Angiuoli S, Jones S, Velculescu VE, Le DT, Diaz LA Jr, Sausen M. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clin Cancer Res. 2019 Sep 10.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/23/7024″,”cancer_type_terms_string”:”Pediatric – Blood Related”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”31506389″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31506389″},{“title”:”Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019 Sep;38(37):6399-6413.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41388-019-0887-2″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Lung Cancer Convergence Research Team: Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-evolution-convergence-team/”,”publisher_year”:”Oncogene, 2019″,”pub_med_id”:”31324888″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31324888″},{“title”:”Hoffman M, Gillmor AH, Kunz DJ, Johnston MJ, Nikolic A, Narta K, Zarrei M, King J, Ellestad K, Dang NH, Cavalli FMG, Kushida MM, Coutinho FJ, Zhu Y, Luu B, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Pugh TJ, Dirks PB, Strother D, Lafay-Cousin L, Resnick AC, Scherer S, Senger DL, Simons BD, Chan JA, Morrissy AS, Gallo M. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019 May 1;79(9):2111-2123.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/9/2111″,”cancer_type_terms_string”:”Brain/Nervous System, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”30877103″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30877103″},{“title”:”Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 Oct 14. pii: 128571.”,”type”:”publication”,”url”:”https://www.jci.org/articles/view/128571″,”cancer_type_terms_string”:”Leukemia (all types)”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”publisher_year”:”Journal of Clinical Investigation, 2019″,”pub_med_id”:”31437130″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31437130″},{“title”:”Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 Aug 28.”,”type”:”publication”,”url”:”https://mcr.aacrjournals.org/content/17/11/2281″,”cancer_type_terms_string”:”Ovarian”,”treatment_type_terms_string”:”Chemotherapy, Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”publisher_year”:”Molecular Cancer Research, 2019″,”pub_med_id”:”31462500″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31462500″},{“title”:”Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019 Mar;25(3):462-469.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-019-0349-y”,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”30742119″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30742119″},{“title”:”Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, Armstrong T, Jaffee EM. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res. 2019 Mar;7(3):428-442.”,”type”:”publication”,”url”:”https://cancerimmunolres.aacrjournals.org/content/7/3/428″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:””,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”publisher_year”:”Cancer Immunology Research, 2019″,”pub_med_id”:”30642833″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30642833″},{“title”:”Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, Ursini-Siegel J, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell. 2019 May 13;35(5):782-797.e8.”,”type”:”publication”,”url”:”https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30199-0″,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Cancer Cell, 2019″,”pub_med_id”:”31085178″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31085178″},{“title”:”Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1204-1213.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/6/1204″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”30573519″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30573519″},{“title”:”MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho FJ, Cavalli FMG, Restall I, Hao X, Hart T, Luchman HA, Weiss S, Dirks PB, Angers S. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Rep. 2019 Apr 16;27(3):971-986.e9.”,”type”:”publication”,”url”:”https://www.cell.com/cell-reports/fulltext/S2211-1247(19)30363-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124719303638%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Chemotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Cell Reports, 2019″,”pub_med_id”:”30995489″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30995489″},{“title”:”Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell. 2019 Jun 27;178(1):160-175.e27.”,”type”:”publication”,”url”:”https://www.cell.com/cell/fulltext/S0092-8674(19)30510-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867419305100%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation–Lustgarten Foundation Pancreatic Cancer Convergence Research Team: Liberating T-Cell Mediated Immunity to Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/mediated-immunity-in-pancreatic-cancer-convergence-team/”,”publisher_year”:”Cell, 2019″,”pub_med_id”:”31155233″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31155233″},{“title”:”Mahadevan KK, Arora KS, Amzallag A, Williams E, Kulkarni AS, Fernandez-Del Castillo C, Lillemoe KD, Bardeesy N, Hong TS, Ferrone CR, Ting DT, Deshpande V. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Mod Pathol. 2019 Jun;32(6):844-854.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41379-018-0196-2″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation–Lustgarten Foundation Pancreatic Cancer Convergence Research Team: Liberating T-Cell Mediated Immunity to Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/mediated-immunity-in-pancreatic-cancer-convergence-team/”,”publisher_year”:”Modern Pathology, 2019″,”pub_med_id”:”30683911″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30683911″},{“title”:”Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E, Han H. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341.”,”type”:”publication”,”url”:”https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(19)30044-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614719300446%3Fshowall%3Dtrue”,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Cancer Research UK–Lustgarten Foundation Pancreatic Cancer Dream Team: Reprogramming of Transcriptional Circuitry to Control Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/reprogramming-of-pancreatic-cancer-dream-team/”,”publisher_year”:”Trends in Pharmacological Science, 2019″,”pub_med_id”:”30975442″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30975442″},{“title”:”Harutyunyan AS, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, Deshmukh S, Chen CCL, Belle J, Mikael LG, Marchione DM, Li R, Nikbakht H, Hu B, Cagnone G, Cheung WA, Mohammadnia A, Bechet D, Faury D, McConechy MK, Pathania M, Jain SU, Ellezam B, Weil AG, Montpetit A, Salomoni P, Pastinen T, Lu C, Lewis PW, Garcia BA, Kleinman CL, Jabado N, Majewski J. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nat Commun. 2019 Mar 19;10(1):1262.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41467-019-09140-x”,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada Cancer Stem Cell Dream Team: Targeting Brain Tumour Stem Cell Epigenetic and Molecular Networks”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-cancer-stem-cell-dream-team/”,”publisher_year”:”Nature Communications, 2019″,”pub_med_id”:”30890717″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30890717″},{“title”:”Wang L, Simons DL, Lu X, Tu TY, Solomon S, Wang R, Rosario A, Avalos C, Schmolze D, Yim J, Waisman J, Lee PP. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol. 2019 Sep;20(9):1220-1230.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41590-019-0429-7″,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–Breast Cancer Research Foundation Breast Cancer Convergence Research Team: Ecology of the Tumor Microenvironment in Breast Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/breast-cancer-tumor-microenvironment/”,”publisher_year”:”Nature Immunology, 2019″,”pub_med_id”:”31285626″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31285626″},{“title”:”Li X, Jolly MK, George JT, Pienta KJ, Levine H. Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment. Front Oncol. 2019 Jan 23;9:10.”,”type”:”publication”,”url”:”https://www.frontiersin.org/articles/10.3389/fonc.2019.00010/full”,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–Breast Cancer Research Foundation Breast Cancer Convergence Research Team: Ecology of the Tumor Microenvironment in Breast Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/breast-cancer-tumor-microenvironment/”,”publisher_year”:”Frontiers in Oncology, 2019″,”pub_med_id”:”30729096″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30729096″},{“title”:”Li X, Gruosso T, Zuo D, Omeroglu A, Meterissian S, Guiot MC, Salazar A, Park M, Levine H. Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3678-3687.”,”type”:”publication”,”url”:”https://www.pnas.org/content/116/9/3678″,”cancer_type_terms_string”:”Breast”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–Breast Cancer Research Foundation Breast Cancer Convergence Research Team: Ecology of the Tumor Microenvironment in Breast Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/breast-cancer-tumor-microenvironment/”,”publisher_year”:”PNAS USA, 2019″,”pub_med_id”:”30733298″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30733298″},{“title”:”Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol. 2019 Apr 1;5(4):e185896.”,”type”:”publication”,”url”:”https://jamanetwork.com/journals/jamaoncology/fullarticle/2720474″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”JAMA Oncology, 2019″,”pub_med_id”:”30629084″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30629084″},{“title”:”Wang Y, Johnson DB, Lu S, Diaz LA Jr, Xu Y, Balko JM. Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. J Immunother Cancer. 2019 May 7;7(1):123.”,”type”:”publication”,”url”:”https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0584-2″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal for Immunotherapy of Cancer, 2019″,”pub_med_id”:”31064401″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31064401″},{“title”:”Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, Ramaswamy AT, Durham JN, Bartlett B, Ma X, Srivastava R, Middha S, Zehir A, Hechtman JF, Morris LG, Weinhold N, Riaz N, Le DT, Diaz LA Jr, Chan TA. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019 May 3;364(6439):485-491.”,”type”:”publication”,”url”:”https://science.sciencemag.org/content/364/6439/485″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Science, 2019″,”pub_med_id”:”31048490″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31048490″},{“title”:”Middha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, Paroder V, Bates DDB, Rana S, Diaz LA Jr, Saltz L, Segal N, Ladanyi M, Zehir A, Hechtman JF. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precis Oncol. 2019;3.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/PO.18.00321″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”JCO Precision Oncology, 2019″,”pub_med_id”:”31008436″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31008436″},{“title”:”Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41575-019-0126-x”,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Nature Reviews. Gastroenterology & Hepatology, 2019″,”pub_med_id”:”30886395″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30886395″},{“title”:”Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J Immunother Cancer. 2019 Feb 11;7(1):40.”,”type”:”publication”,”url”:”https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0492-x”,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal for Immunotherapy of Cancer, 2019″,”pub_med_id”:”30744692″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30744692″},{“title”:”Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan 1;37(1):7-11.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.18.00331″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2019″,”pub_med_id”:”30403571″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30403571″},{“title”:”Yang W, Liu L, Keum N, Qian ZR, Nowak JA, Hamada T, Song M, Cao Y, Nosho K, Smith-Warner SA, Zhang S, Masugi Y, Ng K, Kosumi K, Ma Y, Garrett WS, Wang M, Nan H, Giannakis M, Meyerhardt JA, Chan AT, Fuchs CS, Nishihara R, Wu K, Giovannucci EL, Ogino S, Zhang X. Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. Cancer Prev Res (Phila). 2019 May;12(5):283-294.”,”type”:”publication”,”url”:”https://cancerpreventionresearch.aacrjournals.org/content/12/5/283″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Cancer Prevention Research, 2019″,”pub_med_id”:”30760501″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30760501″},{“title”:”Wasserman I, Lee LH, Ogino S, Marco MR, Wu C, Chen X, Datta J, Sadot E, Szeglin B, Guillem JG, Paty PB, Weiser MR, Nash GM, Saltz L, Barlas A, Manova-Todorova K, Uppada SPB, Elghouayel AE, Ntiamoah P, Glickman JN, Hamada T, Kosumi K, Inamura K, Chan AT, Nishihara R, Cercek A, Ganesh K, Kemeny NE, Dhawan P, Yaeger R, Sawyers CL, Garcia-Aguilar J, Giannakis M, Shia J, Smith JJ. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clin Cancer Res. 2019 Mar 15;25(6):1948-1956.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/6/1948″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”30587545″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30587545″},{“title”:”Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang SK, Murphy CJ, Pauli C, Morris R, Taylor S, Bosch K, Yang S, Wang Y, Van Riper J, Lekaye HC, Roper J, Kim Y, Chen Q, Gross SS, Rhee KY, Cantley LC, Yun J. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019 Mar 22;363(6433):1345-1349.”,”type”:”publication”,”url”:”https://science.sciencemag.org/content/363/6433/1345″,”cancer_type_terms_string”:”Other”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Science, 2019″,”pub_med_id”:”30898933″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30898933″},{“title”:”Ngo B, Van Riper JM, Cantley LC, Yun J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019 May;19(5):271-282.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41568-019-0135-7″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Nature Review Cancer, 2019″,”pub_med_id”:”30967651″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30967651″},{“title”:”Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. J Natl Cancer Inst. 2019 Jan 30.”,”type”:”publication”,”url”:”https://academic.oup.com/jnci/article-abstract/111/9/970/5304460?redirectedFrom=fulltext”,”cancer_type_terms_string”:”Sarcoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Journal of the National Cancer Institute, 2019″,”pub_med_id”:”30698726″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30698726″},{“title”:”Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019 Mar;25(3):470-476.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-018-0339-5″,”cancer_type_terms_string”:”Brain/Nervous System”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”30742120″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30742120″},{“title”:”Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O’Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D’Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 Mar 14. pii: S1470-2045(18)30905-7.”,”type”:”publication”,”url”:”https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30905-7/fulltext”,”cancer_type_terms_string”:”Ovarian”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”publisher_year”:”The Lancet, 2019″,”pub_med_id”:”30880072″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30880072″},{“title”:”Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, St Croix B, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PH, Maris JM, Mackall CL. CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019 Jan 17.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/8/2560″,”cancer_type_terms_string”:”Brain/Nervous System, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”30655315″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30655315″},{“title”:”Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019 Mar;25(3):462-469.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-019-0349-y”,”cancer_type_terms_string”:”Brain/Nervous System, Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Drug Combinations Convergence Research Team: Rational Design of Anticancer Drug Combinations with Dynamic Multi-Dimensional Input”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/rational-design-of-anticancer-drug-combinations-convergence-research-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”30742119″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30742119″},{“title”:”Sethna Z, Elhanati Y, Callan CG Jr, Walczak AM, Mora T. OLGA: fast computation of generation probabilities of B- and T-cell receptor amino acid sequences and motifs. Bioinformatics. 2019 Jan 18.”,”type”:”publication”,”url”:”https://academic.oup.com/bioinformatics/article/35/17/2974/5292315″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation–Lustgarten Foundation Pancreatic Cancer Convergence Research Team: Liberating T-Cell Mediated Immunity to Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/mediated-immunity-in-pancreatic-cancer-convergence-team/”,”publisher_year”:”Bioinformatics, 2019″,”pub_med_id”:”30657870″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30657870″},{“title”:”Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O’Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019 Feb 1;37(4):286-295.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.18.00283″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2019″,”pub_med_id”:”30376427″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30376427″},{“title”:”Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol. 2019 Jan 10:e185896.”,”type”:”publication”,”url”:”https://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.5896″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”JAMA Oncology, 2019″,”pub_med_id”:”30629084″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30629084″},{“title”:”Hamada T, Nowak JA, Masugi Y, Drew DA, Song M, Cao Y, Kosumi K, Mima K, Twombly TS, Liu L, Shi Y, da Silva A, Gu M, Li W, Nosho K, Keum N, Giannakis M, Meyerhardt JA, Wu K, Wang M, Chan AT, Giovannucci EL, Fuchs CS, Nishihara R, Zhang X, Ogino S. Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. J Natl Cancer Inst. 2019 Jan 1;111(1):42-51.”,”type”:”publication”,”url”:”https://academic.oup.com/jnci/article/111/1/42/5127125″,”cancer_type_terms_string”:”Colorectal”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of the National Cancer Institute, 2019″,”pub_med_id”:”30312431″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30312431″},{“title”:”Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan 1;37(1):7-11.”,”type”:”publication”,”url”:”https://ascopubs.org/doi/10.1200/JCO.18.00331″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic, and Immunological Vulnerabilities of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-vulnerabilities-dream-team/”,”publisher_year”:”Journal of Clinical Oncology, 2019″,”pub_med_id”:”30403571″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30403571″},{“title”:”Foster JB, Choudhari N, Perazzelli J, Storm J, Hofmann TJ, Jain P, Storm PB, Pardi N, Weissman D, Waanders AJ, Grupp SA, Karikó K, Resnick AC, Barrett DM. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. Hum Gene Ther. 2019 Feb;30(2):168-178.”,”type”:”publication”,”url”:”https://www.liebertpub.com/doi/10.1089/hum.2018.145″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Human Gene Therapy, 2019″,”pub_med_id”:”30024272″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30024272″},{“title”:”Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, Perdomo C, Schaffer M, Liu G, Zhang S, Liu H, Vick J, Dhillon SS, Platero SJ, Dubinett SM, Stevenson C, Reid ME, Lenburg ME, Spira AE. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun. 2019 Apr 23;10(1):1856.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41467-019-09834-2″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature Communications, 2019″,”pub_med_id”:”31015447″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31015447″},{“title”:”Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019 Mar;567(7749):479-485.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41586-019-1032-7″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature, 2019″,”pub_med_id”:”30894752″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30894752″},{“title”:”Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, Morris TJ, Karpathakis A, Feber A, Breeze CE, Ntolios P, Hynds RE, Falzon M, Capitanio A, Carroll B, Durrenberger PF, Hardavella G, Brown JM, Lynch AG, Farmery H, Paul DS, Chambers RC, McGranahan N, Navani N, Thakrar RM, Swanton C, Beck S, George PJ, Spira A, Campbell P, Thirlwell C, Janes SM. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med. 2019 Mar;25(3):517-525.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-018-0323-0″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Epigenetic Therapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”30664780″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30664780″},{“title”:”Nogalski MT, Solovyov A, Kulkarni AS, Desai N, Oberstein A, Levine AJ, Ting DT, Shenk T, Greenbaum BD. A tumor-specific endogenous repetitive element is induced by herpesviruses. Nat Commun. 2019 Jan 9;10(1):90.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41467-018-07944-x”,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation–Lustgarten Foundation Pancreatic Cancer Convergence Research Team: Liberating T-Cell Mediated Immunity to Pancreatic Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/mediated-immunity-in-pancreatic-cancer-convergence-team/”,”publisher_year”:”Nature Communications, 2019″,”pub_med_id”:”30626867″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30626867″},{“title”:”Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Cancer Res. 2019 Mar 15;79(6):1214-1225.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/6/1214″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Dutch Cancer Society Colorectal Cancer Early Detection Dream Team: Molecular Early Detection of Colorectal Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/colorectal-cancer-early-detection-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”30541742″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30541742″},{“title”:”Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O’Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov. 2019 Feb;9(2):210-219.”,”type”:”publication”,”url”:”https://cancerdiscovery.aacrjournals.org/content/9/2/210″,”cancer_type_terms_string”:”Ovarian”,”treatment_type_terms_string”:”Screening/ Early Detection, Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Ovarian Cancer Research Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: DNA Repair Therapies for Ovarian Cancer”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/dna-repair-thearpies-for-ovarian-cancer-dream-team/”,”publisher_year”:”Cancer Discovery, 2019″,”pub_med_id”:”30425037″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30425037″},{“title”:”Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 Jun;570(7761):385-389.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41586-019-1272-6″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature, 2019″,”pub_med_id”:”31142840″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31142840″},{“title”:”Blundell JR, Schwartz K, Francois D, Fisher DS, Sherlock G, Levy SF. The dynamics of adaptive genetic diversity during the early stages of clonal evolution. Nat Ecol Evol. 2019 Feb;3(2):293-301.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41559-018-0758-1″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Convergence Team”,”research_project”:”SU2C–National Science Foundation Lung Cancer Convergence Research Team: Genetic, Epigenetic, and Immunological Underpinnings of Cancer Evolution Through Treatment”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/convergence-teams/cancer-evolution-convergence-team/”,”publisher_year”:”Nature Ecology & Evolution, 2019″,”pub_med_id”:”30598529″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30598529″},{“title”:”Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/6/1214″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”30541742″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30541742″},{“title”:”Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, Myers DT, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan J, Stein GT, Murchie E, Zarrinkar PP, Janes MR, Li LS, Liu Y, Hata AN, Benes CH. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clin Cancer Res. 2019 Jan 15;25(2):796-807.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/2/796″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/targeting-kras-mutant-lung-cancers-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”30327306″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30327306″},{“title”:”Chu LC, Park S, Kawamoto S, Fouladi DF, Shayesteh S, Zinreich ES, Graves JS, Horton KM, Hruban RH, Yuille AL, Kinzler KW, Vogelstein B, Fishman EK. Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. AJR Am J Roentgenol. 2019 Aug;213(2):349-357.”,”type”:”publication”,”url”:”https://www.ajronline.org/doi/10.2214/AJR.18.20901″,”cancer_type_terms_string”:”Pancreatic”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:””,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Interception Dream Team: Intercepting Pancreatic Cancer in High-Risk Cohorts”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/pancreatic-interception-high-risk-cohorts-dream-team/”,”publisher_year”:”AJR American Journal of Roentgenology, 2019″,”pub_med_id”:”31012758″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31012758″},{“title”:”Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 Apr;33(2):98-110.”,”type”:”publication”,”url”:”https://www.sciencedirect.com/science/article/pii/S088779631830172X?via%3Dihub”,”cancer_type_terms_string”:””,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Transfusion Medicine Reviews, 2019″,”pub_med_id”:”30948292″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30948292″},{“title”:”El-Naggar AM, Clarkson PW, Negri GL, Turgu B, Zhang F, Anglesio MS, Sorensen PH. HACE1 is a potential tumor suppressor in osteosarcoma. Cell Death Dis. 2019 Jan 8;10(1):21.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41419-018-1276-4″,”cancer_type_terms_string”:”Sarcoma”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Cell Death & Disease, 2019″,”pub_med_id”:”30622235″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30622235″},{“title”:”Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019 Mar 12;7(1):70.”,”type”:”publication”,”url”:”https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0538-8″,”cancer_type_terms_string”:”Lymphoma”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Journal for Immunotherapy of Cancer, 2019″,”pub_med_id”:”30871628″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30871628″},{“title”:”Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children’s Oncology Group Phase II Study. Clin Cancer Res. 2019 Jul 29.”,”type”:”publication”,”url”:”https://clincancerres.aacrjournals.org/content/25/20/6044″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Clinical Cancer Research, 2019″,”pub_med_id”:”31358541″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31358541″},{“title”:”Künkele A, Brown C, Beebe A, Mgebroff S, Johnson AJ, Taraseviciute A, Rolczynski LS, Chang CA, Finney OC, Park JR, Jensen MC. Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion. Biol Blood Marrow Transplant. 2019 Feb;25(2):223-232.”,”type”:”publication”,”url”:”https://www.bbmt.org/article/S1083-8791(18)30613-X/fulltext”,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Biology of Blood and Marrow Transplantation, 2019″,”pub_med_id”:”30315942″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30315942″},{“title”:”Vladoiu MC, El-Hamamy I, Donovan LK, Farooq H, Holgado BL, Sundaravadanam Y, Ramaswamy V, Hendrikse LD, Kumar S, Mack SC, Lee JJY, Fong V, Juraschka K, Przelicki D, Michealraj A, Skowron P, Luu B, Suzuki H, Morrissy AS, Cavalli FMG, Garzia L, Daniels C, Wu X, Qazi MA, Singh SK, Chan JA, Marra MA, Malkin D, Dirks P, Heisler L, Pugh T, Ng K, Notta F, Thompson EM, Kleinman CL, Joyner AL, Jabado N, Stein L, Taylor MD. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019 Aug;572(7767):67-73.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41586-019-1158-7″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Nature, 2019″,”pub_med_id”:”31043743″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31043743″},{“title”:”Voeller J, Sondel PM. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169.”,”type”:”publication”,”url”:”https://insights.ovid.com/crossref?an=00043426-201904000-00001″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Journal of Pediatric Hematology/Oncology, 2019″,”pub_med_id”:”30897608″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30897608″},{“title”:”Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP. 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma. Commun Biol. 2019 Feb 26;2:79.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s42003-019-0327-4″,”cancer_type_terms_string”:”Lymphoma”,”treatment_type_terms_string”:”Radiation Therapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Communications Biology, 2019″,”pub_med_id”:”30820474″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=30820474″},{“title”:”Negri GL, Grande BM, Delaidelli A, El-Naggar A, Cochrane D, Lau CC, Triche TJ, Moore RA, Jones SJ, Montpetit A, Marra MA, Malkin D, Morin RD, Sorensen PH. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. J Pathol. 2019 Jun 24.”,”type”:”publication”,”url”:”https://onlinelibrary.wiley.com/doi/abs/10.1002/path.5319″,”cancer_type_terms_string”:”Pediatric – Solid Tumor”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team: Immunogenomics to Create New Therapies for High-Risk Childhood Cancers”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/intractable-pediatric-cancers-dream-team/”,”publisher_year”:”Journal of Pathology, 2019″,”pub_med_id”:”31236944″,”pub_med_url”:”https://www.ncbi.nlm.nih.gov/pubmed/?term=31236944″},{“title”:”Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019 Oct;574(7780):696-701.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41586-019-1671-8″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to Treatable Disease”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/transforming-pancreatic-cancer-dream-team/”,”publisher_year”:”Nature, 2019″,”pub_med_id”:”31645760″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31645760/”},{“title”:”Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N, Pierce J, Kim CS, Ferdous S, Burt DJ, Slane-Tan D, Gomes F, Moore D, Shah R, Al Bakir M, Hiley C, Veeriah S, Summers Y, Crosbie P, Ward S, Mesquita B, Dynowski M, Biswas D, Tugwood J, Blackhall F, Miller C, Hackshaw A, Brady G, Swanton C, Dive C; TRACERx Consortium. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019 Oct;25(10):1534-1539.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-019-0593-1″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”31591595″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31591595/”},{“title”:”Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, Moore DA, Skrzypski M, Abbosh C, Litchfield K, Al Bakir M, Watkins TBK, Veeriah S, Wilson GA, Jamal-Hanjani M, Moldvay J, Botling J, Chinnaiyan AM, Micke P, Hackshaw A, Bartek J, Csabai I, Szallasi Z, Herrero J, McGranahan N, Swanton C; TRACERx Consortium. A clonal expression biomarker associates with lung cancer mortality. Nat Med. 2019 Oct;25(10):1540-1548.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-019-0595-z”,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Screening/ Early Detection”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”31591602″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31591602/”},{“title”:”Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Werner Sunderland M, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx Consortium, Quezada SA, Chain B. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019 Oct;25(10):1549-1559.”,”type”:”publication”,”url”:”https://www.nature.com/articles/s41591-019-0592-2″,”cancer_type_terms_string”:”Lung”,”treatment_type_terms_string”:”Immunotherapy”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team: Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)”,”research_project_url”:”https://standuptocancer.org/research/research-portfolio/dream-teams/lung-cancer-interception-intime-dream-team/”,”publisher_year”:”Nature Medicine, 2019″,”pub_med_id”:”31591606″,”pub_med_url”:”https://pubmed.ncbi.nlm.nih.gov/31591606/”},{“title”:”Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, Tsao MS, Cescon DW, Goldenberg A, Haibe-Kains B. Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. Cancer Res. 2019 Sep 1;79(17):4539-4550.”,”type”:”publication”,”url”:”https://cancerres.aacrjournals.org/content/79/17/4539″,”cancer_type_terms_string”:”Non – site Specific”,”treatment_type_terms_string”:”Other”,”grant_type_terms_string”:”Dream Team”,”research_project”:”SU2C Canada–Canadian Cancer Society Breast Cancer Dream Team: Translational Development of Novel Drugs Targeting Tumor Vulnerabilities”,”research_project_url”:”https://standuptocancer.ca/su2c-canada-canadian-cancer-society-breast-cancer-dream-team/”,”publisher_year”:”Cancer Research, 2019″,”pub_med_id”:”31142"
    }
}